Founded in 1932, Henry Schein, Inc. (HSIC), headquartered in Melville, New York, provides healthcare products and services to dentists and physicians in offices and alternative care settings throughout the world. The company has a market capitalization of $9.2 billion and operates through the global distribution and value-added services, global specialty products, and global technology segments.
The company’s shares have underperformed the broader market over the past year, but have slightly outperformed in 2026. HSIC shares have grown marginally over the past 52 weeks and 3.5% on a year-over-year basis. In comparison, the S&P 500 Index ($SPX) returned 11.8% over the past year and declined marginally in 2026.
To narrow the focus, HSIC has also underperformed the State Street Healthcare Select Sector ETF SPDR (XLV)’s 7.7% gain over the past 52 weeks.
HSIC has become a somewhat worrying stock for investors in recent years. The company has not seen organic revenue growth over the past two years, suggesting that future acquisitions, which would require significant capital expenditures, may be necessary to drive growth. Additionally, HSIC has seen a 2.8% decline in its free cash flow margin over the past five years, reflecting increased investment to defend its market position.
Most recently, the stock closed down more than 2% after naming Fedd Lowery as the next CEO, replacing Stanley Begman, who previously said he would retire effective March 2. This news was bad for investors, causing its price to drop in the trading session.
For the current year ending December 2025, analysts expect HSIC’s EPS to grow 3.6% year-over-year to $4.91 on a diluted basis. The company’s history of earnings surprises is mixed. It beat or met the consensus estimate in three of the last four quarters and missed the figure on one occasion.
Among the 16 analysts covering HSIC stock, the consensus is a “moderate buy.” This is based on six “Strong Buy” ratings, nine “Holds” and one “Strong Sell” ratings.
On Jan. 20, Mizuho Securities analyst Steven Valiquette maintained a “Hold” rating on Henry Schein shares and set a price target of $81. HSIC’s average price target of $78.14 is below its current market prices. Its street high target of $90 suggests the stock could rise as much as 15.1%.
On the date of publication, Anushka Mukherjee did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com